Guardant Health Inc. Common Stock vs GeneDx Holdings Corp — how do they compare? Guardant Health Inc. Common Stock trades at $168.65 (market cap $22.22B), while GeneDx Holdings Corp trades at $67.92 (market cap $2.02B). The key difference: Guardant Health Inc. Common Stock is far larger — about 11× GeneDx Holdings Corp's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 0 Days and GeneDx Holdings Corp for 19 Days on average.
| GH | WGS | |
|---|---|---|
Market Cap | $22.22B | $2.02B |
Volume | 1,589,453 | 734,640 |
Sector | Health | Health |
52-Week High | $187.22 | $167.51 |
52-Week Low | $61.73 | $34.51 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $22.86B | $2.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →